Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Inspira Technologies Oxy BHN ( (IINN) ) is now available.
On February 17, 2026, Israel-based Inspira Technologies announced it had deployed its FDA-cleared INSPIRA ART100 cardiopulmonary support system at an additional leading U.S. academic medical center in New York. The hospital, ranked among the state’s top 10 in Newsweek’s World’s Best Hospitals 2025 list, has integrated the device into its clinical workflow for a structured commercial evaluation aimed at defining protocols and assessing broader institutional use.
The move expands Inspira’s reach in the Tier-1 U.S. hospital market and builds on prior FDA clearance and earlier commercial activity at other major healthcare facilities. Management framed the New York deployment as a key step in its U.S. commercial strategy, highlighting the goal of turning high-profile hospital evaluations into a recurring revenue pipeline and deepening the company’s footprint across key U.S. markets.
The most recent analyst rating on (IINN) stock is a Sell with a $0.68 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Spark’s Take on IINN Stock
According to Spark, TipRanks’ AI Analyst, IINN is a Neutral.
The score is held down primarily by weak financial performance—minimal/erratic revenue, negative gross profit, ongoing net losses, and significant cash burn—implying continued dependence on external funding. Technical indicators are broadly neutral, offering limited offset, while valuation metrics provide little support due to a negative P/E and no dividend yield.
To see Spark’s full report on IINN stock, click here.
More about Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd. is a commercial-stage medical device company focused on advanced respiratory support and real-time blood monitoring solutions. Its FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., and underpins development of the INSPIRA ART500 and the HYLA continuous, non-invasive blood sensor platform, positioning the firm within the life-support MedTech market.
Average Trading Volume: 590,523
Technical Sentiment Signal: Sell
Current Market Cap: $24.19M
See more data about IINN stock on TipRanks’ Stock Analysis page.